Prostate-specific membrane antigen is produced in tumor-associated neovasculature
- PMID: 10537328
Prostate-specific membrane antigen is produced in tumor-associated neovasculature
Abstract
Prostate-specific membrane antigen (PSMA), a type II transmembrane protein, was originally thought to be strictly expressed in prostatic tissue, but recent studies have demonstrated PSMA protein expression in nonprostatic tumor neovasculature as well. Using immunohistochemistry, reverse transcription-PCR assays, and in situ hybridization, we have demonstrated PSMA mRNA transcripts and protein expression in the endothelium of tumor-associated neovasculature of multiple nonprostatic solid malignancies. In addition, we found no PSMA mRNA or protein expression in the vascular endothelial cells of corresponding benign tissue examples. Our findings expand the possible therapeutic role of PSMA and establish it as a unique biomarker specifically produced and expressed by tumor-associated neovasculature but not produced or expressed by normal vessels.
Similar articles
-
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.Cancer Res. 1999 Jul 1;59(13):3192-8. Cancer Res. 1999. PMID: 10397265
-
Prostate-specific membrane antigen expression in normal and malignant human tissues.Clin Cancer Res. 1997 Jan;3(1):81-5. Clin Cancer Res. 1997. PMID: 9815541
-
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.Int J Cancer. 2003 Nov 1;107(2):323-9. doi: 10.1002/ijc.11402. Int J Cancer. 2003. PMID: 12949815
-
[Detection of PSA mRNA and PSMA mRNA by RT-PCR].Nihon Rinsho. 2002 Dec;60 Suppl 11:151-5. Nihon Rinsho. 2002. PMID: 12599562 Review. Japanese. No abstract available.
-
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.Urology. 1998 Oct;52(4):637-40. doi: 10.1016/s0090-4295(98)00278-7. Urology. 1998. PMID: 9763084 Review.
Cited by
-
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-_targeted α-Particle Radiopharmaceutical Therapy.J Nucl Med. 2016 Oct;57(10):1569-1575. doi: 10.2967/jnumed.116.174300. Epub 2016 May 26. J Nucl Med. 2016. PMID: 27230930 Free PMC article.
-
A peculiar distribution on 18F-DCFPyL-PSMA PET scan for a patient with prostate cancer and protein S deficiency.Radiol Case Rep. 2024 Jul 16;19(10):4122-4126. doi: 10.1016/j.radcr.2024.06.021. eCollection 2024 Oct. Radiol Case Rep. 2024. PMID: 39114866 Free PMC article.
-
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.Sci Transl Med. 2012 Jun 27;4(140):140ra86. doi: 10.1126/scitranslmed.3003886. Sci Transl Med. 2012. PMID: 22745436 Free PMC article. Clinical Trial.
-
Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.Br J Cancer. 2016 Apr 26;114(9):986-94. doi: 10.1038/bjc.2016.72. Br J Cancer. 2016. PMID: 27115568 Free PMC article. Clinical Trial.
-
Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.J Med Chem. 2008 Dec 25;51(24):7737-43. doi: 10.1021/jm800765e. J Med Chem. 2008. PMID: 19053759 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous